30. Referanser

Abramson, J. S., Ku, M., Hertzberg, M., Huang, H. Q., Fox, C. P., Zhang, H., Yoon, D. H., Kim, W. S., ... Gregory, G. P. (2024). Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial. Lancet, 404(10466), 1940-1954.

Abramson, J. S., Palomba, M. L., Gordon, L. I., Lunning, M. A., Wang, M., Arnason, J., Mehta, A., Purev, E., ... Siddiqi, T. (2020). Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet, 396(10254), 839-852.

Advani, R. H., Horning, S. J., Hoppe, R. T., Daadi, S., Allen, J., Natkunam, Y., & Bartlett, N. L. (2014). Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma. Journal of clinical oncology, 32(9), 912-8.

Alaggio, R., Amador, C., Anagnostopoulos, I., Attygalle, A. D., Araujo, I. B. O., Berti, E., Bhagat, G., Borges, A. M., ... Xiao, W. (2022). The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia, 36(7), 1720-1748.

Anderlini, P., Saliba, R., Acholonu, S., Giralt, S. A., Andersson, B., Ueno, N. T., Hosing, C., Khouri, I. F., ... Champlin, R. E. (2008). Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience. Haematologica, 93(2), 257-64.

Anderson, R. A., Remedios, R., Kirkwood, A. A., Patrick, P., Stevens, L., Clifton-Hadley, L., Roberts, T., Hatton, C., ... Johnson, P. W. M. (2018). Determinants of ovarian function after response-adapted therapy in patients with advanced Hodgkin's lymphoma (RATHL): a secondary analysis of a randomised phase 3 trial. The Lancet. Oncology, 19(10), 1328-1337.

Andre, M. P. E., Girinsky, T., Federico, M., Reman, O., Fortpied, C., Gotti, M., Casasnovas, O., Brice, P., ... Raemaekers, J. (2017). Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial. Journal of clinical oncology, 35(16), 1786-1794.

Ansell, S. M., Radford, J., Connors, J. M., Długosz-Danecka, M., Kim, W. S., Gallamini, A., Ramchandren, R., Friedberg, J. W., ... Straus, D. J. (2022). Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma. New England journal of medicine, 387(4), 310-320.

Ardeshna, K. M., Qian, W., Smith, P., Braganca, N., Lowry, L., Patrick, P., Warden, J., Stevens, L., ... Linch, D. C. (2014). Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial. The Lancet. Oncology, 15(4), 424-35.

Arun Kumar, S., Gao, J., & Patel, S. A. (2023). The shifting therapeutic paradigm for relapsed/refractory mantle cell lymphoma. Leukemia research, 134, 107385.

Barrington, S. F., Mikhaeel, N. G., Kostakoglu, L., Meignan, M., Hutchings, M., Mueller, S. P., Schwartz, L. H., Zucca, E., ... Cheson, B. D. (2014). Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. Journal of clinical oncology, 32(27), 3048-58.

Barzenje, D. A., Holte, H., Fosså, A., Ghanima, W., Liestøl, K., Delabie, J., & Kolstad, A. (2017). Long-term outcome for patients with early stage marginal zone lymphoma and mantle cell lymphoma. Leukemia & lymphoma, 58(3), 623-632.

Barzenje, D. A., Kolstad, A., Ghanima, W., & Holte, H. (2018). Long-term outcome of patients with solitary plasmacytoma treated with radiotherapy: A population-based, single-center study with median follow-up of 13.7 years. Hematological oncology, 36(1), 217-223.

Bašić-Kinda, S., Radman, I., Dujmović, D., Ilić, I., Kralik, M., Dobrenić, M., Galunić-Bilić, L., Rončević, P., ... Aurer, I. (2021). R-CHOEP14 in younger high-risk patients with large B cell lymphoma: an effective front-line regimen with cardiac toxicity: a real-life, single-center experience. Annals of hematology, 100(6), 1517-1524.

Bastings, L., Beerendonk, C. C., Westphal, J. R., Massuger, L. F., Kaal, S. E., van Leeuwen, F. E., Braat, D. D., & Peek, R. (2013). Autotransplantation of cryopreserved ovarian tissue in cancer survivors and the risk of reintroducing malignancy: a systematic review. Human reproduction update, 19(5), 483-506.

Behringer, K., Mueller, H., Goergen, H., Thielen, I., Eibl, A. D., Stumpf, V., Wessels, C., Wiehlputz, M., ... Borchmann, P. (2013). Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials. Journal of clinical oncology, 31(2), 231-9.

Behringer, K., Thielen, I., Mueller, H., Goergen, H., Eibl, A. D., Rosenbrock, J., Halbsguth, T., Eichenauer, D. A., ... Borchmann, P. (2012). Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial. Annals of oncology, 23(7), 1818-25.

Behringer, K., Wildt, L., Mueller, H., Mattle, V., Ganitis, P., van den Hoonaard, B., Ott, H. W., Hofer, S., ... Borchmann, P. (2010). No protection of the ovarian follicle pool with the use of GnRH-analogues or oral contraceptives in young women treated with escalated BEACOPP for advanced-stage Hodgkin lymphoma. Final results of a phase II trial from the German Hodgkin Study Group. Annals of oncology, 21(10), 2052-60.

Bennett, M., Sharma, K., Yegena, S., Gavish, I., Dave, H. P., & Schechter, G. P. (2005). Rituximab monotherapy for splenic marginal zone lymphoma. Haematologica, 90(6), 856-8.

Bersvendsen, H., Kolstad, A., Blystad, A. K., Aurlien, E., Fosså, A., Kvaløy, S. O., Holte, H., & Lauritzsen, G. F. (2014). Multimodal treatment with ALL-like chemotherapy, Auto-SCT and radiotherapy for lymphoblastic lymphoma. Acta oncologica, 53(5), 680-7.

Bertoni, F., & Zucca, E. (2005). State-of-the-art therapeutics: marginal-zone lymphoma. Journal of clinical oncology, 23(26), 6415-20.

Björkholm, M., Weibull, C. E., Eloranta, S., Smedby, K. E., Glimelius, I., & Dickman, P. W. (2018). Greater attention should be paid to developing therapies for elderly patients with Hodgkin lymphoma-A population-based study from Sweden. European journal of haematology, 101(1), 106-114.

Blaker, Y. N., Eide, M. B., Liestøl, K., Lauritzsen, G. F., Kolstad, A., Fosså, A., Smeland, E. B., & Holte, H. (2014). High dose chemotherapy with autologous stem cell transplant for patients with transformed B-cell non-Hodgkin lymphoma in the rituximab era. Leukemia & lymphoma, 55(10), 2319-27.

Boeckh, M., & Ljungman, P. (2009). How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood, 113(23), 5711-9.

Boehme, V., Zeynalova, S., Kloess, M., Loeffler, M., Kaiser, U., Pfreundschuh, M., Schmitz, N., & German High-Grade Non-Hodgkin's Lymphoma Study Group (2007). Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Annals of oncology, 18(1), 149-57.

Bologna, S., Vander Borght, T., Briere, J., Ribrag, V., Damaj, G. L., Thieblemont, C., Feugier, P., Peyrade, F., ... Bastie, J. N. (2021). Early positron emission tomography response adapted treatment in localized diffuse large B-cell lymphoma (AAIPI = 0): results of the phase 3 LYSA LNH 09-1B trial. Hematological oncology, 39(S2), 31-32.

Borchmann, P., Ferdinandus, J., Schneider, G., Moccia, A., Greil, R., Hertzberg, M., Schaub, V., Hüttmann, A., ... Diehl, V. (2024). Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial. Lancet, 404(10450), 341-352.

Borchmann, P., Goergen, H., Kobe, C., Lohri, A., Greil, R., Eichenauer, D. A., Zijlstra, J. M., Markova, J., ... Engert, A. (2018). PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. Lancet, 390(10114), 2790-2802.

Borchmann, P., Plütschow, A., Kobe, C., Greil, R., Meissner, J., Topp, M. S., Ostermann, H., Dierlamm, J., ... Engert, A. (2021). PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial. The Lancet. Oncology, 22(2), 223-234.

Boue, F., Gabarre, J., Gisselbrecht, C., Reynes, J., Cheret, A., Bonnet, F., Billaud, E., Raphael, M., ... Costagliola, D. (2006). Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma. Journal of clinical oncology, 24(25), 4123-8.

Brice, P., Bastion, Y., Lepage, E., Brousse, N., Haïoun, C., Moreau, P., Straetmans, N., Tilly, H., ... Solal-Céligny, P. (1997). Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. Journal of clinical oncology, 15(3), 1110-7.

Brody, J. D., Jørgensen, J., Belada, D., Costello, R., Trněný, M., Vitolo, U., Lewis, D. J., Karimi, Y. H., ... Cordoba, R. (2025). Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial. Blood, 145(15), 1621-1631.

Caimi, P. F., Ai, W., Alderuccio, J. P., Ardeshna, K. M., Hamadani, M., Hess, B., Kahl, B. S., Radford, J., ... Carlo-Stella, C. (2021). Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. The Lancet. Oncology, 22(6), 790-800.

Campo, E., Jaffe, E. S., Cook, J. R., Quintanilla-Martinez, L., Swerdlow, S. H., Anderson, K. C., Brousset, P., Cerroni, L., ... Zelenetz, A. D. (2022). The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood, 140(11), 1229-1253.

Camus, V., Rossi, C., Sesques, P., Lequesne, J., Tonnelet, D., Haioun, C., Durot, E., Willaume, A., ... Tilly, H. (2021). Outcomes after first-line immunochemotherapy for primary mediastinal B-cell lymphoma: a LYSA study. Blood advances, 5(19), 3862-3872.

Canellos, G. P., Anderson, J. R., Propert, K. J., Nissen, N., Cooper, M. R., Henderson, E. S., Green, M. R., Gottlieb, A., & Peterson, B. A. (1992). Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. New England journal of medicine, 327(21), 1478-84.

Carter, A., Robison, L. L., Francisco, L., Smith, D., Grant, M., Baker, K. S., Gurney, J. G., McGlave, P. B., ... Bhatia, S. (2006). Prevalence of conception and pregnancy outcomes after hematopoietic cell transplantation: report from the Bone Marrow Transplant Survivor Study. Bone marrow transplantation, 37(11), 1023-9.

Casasnovas, R. O., Bouabdallah, R., Brice, P., Lazarovici, J., Ghesquieres, H., Stamatoullas, A., Dupuis, J., Gac, A. C., ... Meignan, M. (2019). PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study. The Lancet. Oncology, 20(2), 202-215.

Casulo, C., & Barr, P. M. (2019). How I treat early-relapsing follicular lymphoma. Blood, 133(14), 1540-1547.

Cavalli, F., Isaacson, P. G., Gascoyne, R. D., & Zucca, E. (2001). MALT Lymphomas. Hematology. American Society of Hematology. Education Program, (1), 241-58.

Cerhan, J. R., & Slager, S. L. (2015). Familial predisposition and genetic risk factors for lymphoma. Blood, 126(20), 2265-73.

Chamberlain, M. C., Nolan, C., & Abrey, L. E. (2005). Leukemic and lymphomatous meningitis: incidence, prognosis and treatment. Journal of neuro-oncology, 75(1), 71-83.

Cheah, C. Y., Wirth, A., & Seymour, J. F. (2014). Primary testicular lymphoma. Blood, 123(4), 486-93.

Cheson, B. D., Chua, N., Mayer, J., Dueck, G., Bouabdallah, K., Fowler, N., Delwail, V., Press, O., ... Sehn, L. H. (2018). Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study. Journal of clinical oncology, 36(22), 2259-2266.

Cheson, B. D., Fisher, R. I., Barrington, S. F., Cavalli, F., Schwartz, L. H., Zucca, E., Lister, T. A., Alliance, A. L., ... United Kingdom National Cancer Research Institute (2014). Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. Journal of clinical oncology, 32(27), 3059-68.

Cheson, B. D., Horning, S. J., Coiffier, B., Shipp, M. A., Fisher, R. I., Connors, J. M., Lister, T. A., Vose, J., ... Canellos, G. P. (1999). Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. Journal of clinical oncology, 17(4), 1244.

Cheson, B. D., Pfistner, B., Juweid, M. E., Gascoyne, R. D., Specht, L., Horning, S. J., Coiffier, B., Fisher, R. I., ... International Harmonization Project on Lymphoma (2007). Revised response criteria for malignant lymphoma. Journal of clinical oncology, 25(5), 579-86.

Chopp, L., Redmond, C., O'Shea, J. J., & Schwartz, D. M. (2023). From thymus to tissues and tumors: A review of T-cell biology. Journal of allergy and clinical immunology, 151(1), 81-97.

Coiffier, B., Lepage, E., Briere, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., ... Gisselbrecht, C. (2002). CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. New England journal of medicine, 346(4), 235-42.

Cook, M. R., Williams, L. S., Dorris, C. S., Luo, Y., Makambi, K., & Dunleavy, K. (2024). Improved survival for dose-intensive chemotherapy in primary mediastinal B-cell lymphoma: a systematic review and meta-analysis of 4,068 patients. Haematologica, 109(3), 846-856.

Crump, M., Kuruvilla, J., Couban, S., MacDonald, D. A., Kukreti, V., Kouroukis, C. T., Rubinger, M., Buckstein, R., ... Shepherd, L. E. (2014). Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. Journal of clinical oncology, 32(31), 3490-6.

Curt, G. A., Breitbart, W., Cella, D., Groopman, J. E., Horning, S. J., Itri, L. M., Johnson, D. H., Miaskowski, C., ... Vogelzang, N. J. (2000). Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. The oncologist, 5(5), 353-60.

Czuczman, M. S., Grillo-Lopez, A. J., White, C. A., Saleh, M., Gordon, L., LoBuglio, A. F., Jonas, C., Klippenstein, D., ... Varns, C. (1999). Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. Journal of clinical oncology, 17(1), 268-76.

d'Amore, F., Relander, T., Lauritzsen, G. F., Jantunen, E., Hagberg, H., Anderson, H., Holte, H., Osterborg, A., ... Toldbod, H. E. (2012). Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. Journal of clinical oncology, 30(25), 3093-9.

Dabaja, B. S., Ng, A. K., Terezakis, S. A., Plastaras, J. P., Yunes, M., Wilson, L. D., Specht, L., & Yahalom, J. (2020). Making Every Single Gray Count: Involved Site Radiation Therapy Delineation Guidelines for Hematological Malignancies. International journal of radiation oncology, biology, physics, 106(2), 279-281.

Dabaja, B. S., Ng, A. K., Terezakis, S. A., Plastaras, J. P., Yunes, M., Wilson, L. D., Yang, J., Gunther, J. R., ... Yahalom, J. (2020). ILROG Lymphoma Mini-Atlas Part II, Hodgkin Lymphoma. International journal of radiation oncology, biology, physics, 108(4), 977-978.

Dahl, O., Lehne, G., Christoffersen, T. (2016). Medikamentell kreftbehandling: cytostatikaboken. Universitetet i Oslo, Avdeling for farmakologi.

Dean, R. M., Fowler, D. H., Wilson, W. H., Odom, J., Steinberg, S. M., Chow, C., Kasten-Sportes, C., Gress, R. E., & Bishop, M. R. (2005). Efficacy of reduced-intensity allogeneic stem cell transplantation in chemotherapy-refractory non-hodgkin lymphoma. Biology of blood and marrow transplantation, 11(8), 593-9.

Dearden, C. (2006). The role of alemtuzumab in the management of T-cell malignancies. Seminars in oncology, 33(2 Suppl 5), S44-52.

Delabie, J., Holte, H., Vose, J. M., Ullrich, F., Jaffe, E. S., Savage, K. J., Connors, J. M., Rimsza, L., ... Weisenburger, D. D. (2011). Enteropathy-associated T-cell lymphoma: clinical and histological findings from the international peripheral T-cell lymphoma project. Blood, 118(1), 148-55.

Demeestere, I., Brice, P., Peccatori, F. A., Kentos, A., Dupuis, J., Zachee, P., Casasnovas, O., Van Den Neste, E., ... Englert, Y. (2016). No Evidence for the Benefit of Gonadotropin-Releasing Hormone Agonist in Preserving Ovarian Function and Fertility in Lymphoma Survivors Treated With Chemotherapy: Final Long-Term Report of a Prospective Randomized Trial. Journal of clinical oncology, 34(22), 2568-74.

Desai, S. H., Spinner, M. A., David, K., Bachanova, V., Goyal, G., Kahl, B., Dorritie, K., Azzi, J., ... Micallef, I. N. (2023). Checkpoint inhibitor-based salvage regimens prior to autologous stem cell transplant improve event-free survival in relapsed/refractory classic Hodgkin lymphoma. American journal of hematology, 98(3), 464-471.

Diamond, C., Taylor, T. H., Im, T., Miradi, M., & Anton-Culver, H. (2006). Improved survival and chemotherapy response among patients with AIDS-related non-Hodgkin's lymphoma receiving highly active antiretroviral therapy. Hematological oncology, 24(3), 139-45.

Dickinson, M., Carlo-Stella, C., Morschhauser, F., Bachy, E., Corradini, P., Iacoboni, G., Khan, C., Wrobel, T., ... Hutchings, M. (2022). Glofitamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and ≥ 2 prior therapies: Pivotal phase II expansion results. Journal of clinical oncology, 40(16_suppl), 7500-7500.

Diehl, V., Franklin, J., Pfreundschuh, M., Lathan, B., Paulus, U., Hasenclever, D., Tesch, H., Herrmann, R., ... German Hodgkin's Lymphoma Study Group (2003). Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. New England journal of medicine, 348(24), 2386-95.

Diehl, V., Sextro, M., Franklin, J., Hansmann, M. L., Harris, N., Jaffe, E., Poppema, S., Harris, M., ... Stein, H. (1999). Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease. Journal of clinical oncology, 17(3), 776-83.

Dimeo, F. C., Stieglitz, R. D., Novelli-Fischer, U., Fetscher, S., & Keul, J. (1999). Effects of physical activity on the fatigue and psychologic status of cancer patients during chemotherapy. Cancer, 85(10), 2273-7.

Dreger, P., Brand, R., Milligan, D., Corradini, P., Finke, J., Lambertenghi Deliliers, G., Martino, R., Russell, N., ... Chronic Leukemia Working Party of the Ebmt (2005). Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis. Leukemia, 19(6), 1029-33.

Dreyling, M., Doorduijn, J., Giné, E., Jerkeman, M., Walewski, J., Hutchings, M., Mey, U., Riise, J., ... Hoster, E. (2024). Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network. Lancet, 403(10441), 2293-2306.

Dreyling, M., Doorduijn, J. K., Gine, E., Jerkeman, M., Walewski, J., Hutchings, M., Mey, U., Riise, J., ... Hoster, E. (2024). Role of Autologous Stem Cell Transplantation in the Context of Ibrutinib-Containing First-Line Treatment in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network. Blood, 144(Suppl 1), 240.

Dreyling, M., Jurczak, W., Jerkeman, M., Silva, R. S., Rusconi, C., Trneny, M., Offner, F., Caballero, D., ... Rule, S. (2016). Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Lancet, 387(10020), 770-8.

Dundee, J. W., Yang, J., & McMillan, C. (1991). Non-invasive stimulation of the P6 (Neiguan) antiemetic acupuncture point in cancer chemotherapy. Journal of the Royal Society of Medicine, 84(4), 210-2.

Duvic, M., Tetzlaff, M. T., Gangar, P., Clos, A. L., Sui, D., & Talpur, R. (2015). Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis. Journal of clinical oncology, 33(32), 3759-65.

ECOG-ACRIN Cancer Research Group (2024). ECOG Performance Status Scale. [nettdokument]. Boston, MA: ECOG-ACRIN. Hentet 2024 fra https://ecog-acrin.org/resources/ecog-performance-status/

Eichenauer, D. A., Kreissl, S., Bühnen, I., Baues, C., Kobe, C., van Heek, L., Goergen, H., Fuchs, M., ... Borchmann, P. (2021). PET-2-guided escalated BEACOPP for advanced nodular lymphocyte-predominant Hodgkin lymphoma: a subgroup analysis of the randomized German Hodgkin Study Group HD18 study. Annals of oncology, 32(6), 807-810.

Eichenauer, D. A., Plütschow, A., Fuchs, M., Hartmann, S., Hansmann, M. L., Böll, B., von Tresckow, B., Borchmann, P., & Engert, A. (2020). Rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: long-term follow-up of a phase 2 study from the German Hodgkin Study Group. Leukemia, 34(3), 953-956.

Eichenauer, D. A., Plütschow, A., Fuchs, M., Sasse, S., Baues, C., Böll, B., von Tresckow, B., Diehl, V., ... Engert, A. (2020). Long-Term Follow-Up of Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma Treated in the HD7 to HD15 Trials: A Report From the German Hodgkin Study Group. Journal of clinical oncology, 38(7), 698-705.

Eichenauer, D. A., Plütschow, A., Fuchs, M., von Tresckow, B., Böll, B., Behringer, K., Diehl, V., Eich, H. T., ... Engert, A. (2015). Long-Term Course of Patients With Stage IA Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the German Hodgkin Study Group. Journal of clinical oncology, 33(26), 2857-62.

Eichenauer, D. A., Plütschow, A., Schröder, L., Fuchs, M., Böll, B., von Tresckow, B., Diehl, V., Borchmann, P., & Engert, A. (2018). Relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group. Blood, 132(14), 1519-1525.

Eide, M. B., Lauritzsen, G. F., Kvalheim, G., Kolstad, A., Fagerli, U. M., Maisenhölder, M., Ostenstad, B., Fluge, O., ... Holte, H. (2011). High dose chemotherapy with autologous stem cell support for patients with histologically transformed B-cell non-Hodgkin lymphomas. A Norwegian multi centre phase II study. British journal of haematology, 152(5), 600-10.

Ekström-Smedby, K. (2006). Epidemiology and etiology of non-Hodgkin lymphoma--a review. Acta oncologica, 45(3), 258-71.

El-Galaly, T. C., Villa, D., Michaelsen, T. Y., Hutchings, M., Mikhaeel, N. G., Savage, K. J., Sehn, L. H., Barrington, S., ... Cheah, C. Y. (2017). The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: An international multicenter study of 1532 patients treated with chemoimmunotherapy. European journal of cancer, 75, 195-203.

Elis, A., Blickstein, D., Klein, O., Eliav-Ronen, R., Manor, Y., & Lishner, M. (2002). Detection of relapse in non-Hodgkin's lymphoma: role of routine follow-up studies. American journal of hematology, 69(1), 41-4.

Ellin, F., Maurer, M. J., Srour, L., Farooq, U., Jerkeman, M., Connors, J. M., Smedby, K. E., Bennani, N. N., ... Savage, K. J. (2019). Comparison of the NCCN-IPI, the IPI and PIT scores as prognostic tools in peripheral T-cell lymphomas. British journal of haematology, 186(3), e24-e27.

Engert, A., Franklin, J., Eich, H. T., Brillant, C., Sehlen, S., Cartoni, C., Herrmann, R., Pfreundschuh, M., ... Diehl, V. (2007). Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial. Journal of clinical oncology, 25(23), 3495-502.

Engert, A., Plutschow, A., Eich, H. T., Lohri, A., Dorken, B., Borchmann, P., Berger, B., Greil, R., ... Diehl, V. (2010). Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. New England journal of medicine, 363(7), 640-52.

Engert, A., Schiller, P., Josting, A., Herrmann, R., Koch, P., Sieber, M., Boissevain, F., De Wit, M., ... German Hodgkin's Lymphoma Study Group (2003). Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. Journal of clinical oncology, 21(19), 3601-8.

Evens, A. M., Querfeld, C., & Rosen, S. T. (2006). T-cell non-Hogdkin's lymphoma. Cancer treatment and research, 131, 161-220.

Eyre, T. A., Djebbari, F., Kirkwood, A. A., & Collins, G. P. (2020). Efficacy of central nervous system prophylaxis with stand-alone intrathecal chemotherapy in diffuse large B-cell lymphoma patients treated with anthracycline-based chemotherapy in the rituximab era: a systematic review. Haematologica, 105(7), 1914-1924.

Ezzat, H., Filipenko, D., Vickars, L., Galbraith, P., Li, C., Murphy, K., Montaner, J. S., Harris, M., ... Leitch, H. A. (2007). Improved survival in HIV-associated diffuse large B-cell lymphoma with the addition of rituximab to chemotherapy in patients receiving highly active antiretroviral therapy. HIV clinical trials, 8(3), 132-44.

Ezzo, J., Vickers, A., Richardson, M. A., Allen, C., Dibble, S. L., Issell, B., Lao, L., Pearl, M., ... Zhang, G. (2005). Acupuncture-point stimulation for chemotherapy-induced nausea and vomiting. Journal of clinical oncology, 23(28), 7188-98.

Falchi, L., Nijland, M., Huang, H., Linton, K. M., Seymour, J. F., Tao, R., Kwiatek, M., Costa, A., ... Morschhauser, F. (2026). Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial. Lancet, 407(10524), 161-173.

Federico, M., Bellei, M., Marcheselli, L., Luminari, S., Lopez-Guillermo, A., Vitolo, U., Pro, B., Pileri, S., ... Solal-Celigny, P. (2009). Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. Journal of clinical oncology, 27(27), 4555-62.

Federico, M., Fortpied, C., Stepanishyna, Y., Gotti, M., van der Maazen, R., Cristinelli, C., Re, A., Plattel, W., ... André, M. (2024). Long-Term Follow-Up of the Response-Adapted Intergroup EORTC/LYSA/FIL H10 Trial for Localized Hodgkin Lymphoma. Journal of clinical oncology, 42(1), 19-25.

Ferdinandus, J., Kaul, H., Fosså, A., Hüttmann, A., Keil, F., Ko, Y. D., Hitz, F., Schwarz, M., ... Bröckelmann, P. J. (2025). Positron Emission Tomography-Guided Brentuximab Vedotin, Etoposide, Cyclophosphamide, Doxorubicin, Dacarbazine, and Dexamethasone in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma: A Prospective, Multicenter, Single-Arm, Phase II Cohort of the German Hodgkin Study Group HD21 Trial. Journal of clinical oncology, 43(27), 2974-2985.

Ferdinandus, J., Schneider, G., Moccia, A., Greil, R., Hertzberg, M., Schaub, V., Hüttmann, A., Keil, F., ... Behringer, K. (2025). Fertility in patients with advanced-stage classic Hodgkin lymphoma treated with BrECADD versus eBEACOPP: a secondary analysis of the multicentre, randomised, parallel, open-label, phase 3 HD21 trial. The Lancet. Oncology, 26(8), 1081-1090.

Ferreri, A. J., Cwynarski, K., Pulczynski, E., Ponzoni, M., Deckert, M., Politi, L. S., Torri, V., Fox, C. P., ... International Extranodal Lymphoma Study Group (2016). Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. The Lancet. Haematology, 3(5), e217-27.

Ferreri, A. J., Reni, M., Foppoli, M., Martelli, M., Pangalis, G. A., Frezzato, M., Cabras, M. G., Fabbri, A., ... International Extranodal Lymphoma Study Group (2009). High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet, 374(9700), 1512-20.

Ferreri, A. J. M., Cwynarski, K., Pulczynski, E., Fox, C. P., Schorb, E., Celico, C., Falautano, M., Nonis, A., ... Illerhaus, G. (2022). Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial. Leukemia, 36(7), 1870-1878.

Ferreri, A. J. M., Cwynarski, K., Pulczynski, E., Fox, C. P., Schorb, E., La Rosee, P., Binder, M., Fabbri, A., ... International Extranodal Lymphoma Study Group (2017). Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. The Lancet. Haematology, 4(11), e510-e523.

Ferreri, A. J. M., Doorduijn, J. K., Re, A., Cabras, M. G., Smith, J., Ilariucci, F., Luppi, M., Calimeri, T., ... Cwynarski, K. (2021). MATRix-RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial. The Lancet. Haematology, 8(2), e110-e121.

FHI (2026). Årsrapport 2025 med resultater og forbedringstiltak fra Nasjonalt kvalitetsregister for lymfoide maligniteter. Oslo: Folkehelseinstituttet, Kreftregisteret. Hentet fra https://www.fhi.no/contentassets/6c009c388b0e413c9f50135d6bfc60e6/arsrapport-2025-nasjonalt-kvalitetsregister-for-lymfoide-maligniteter-1.pdf

Flerlage, J. E., Eichenauer, D. A., Fuchs, M., Hartmann, S., Eich, H. T., Savage, K. J., Lo, A. C., Skinnider, B., ... Binkley, M. S. (2026). Historical outcomes for patients with stage IA NLPHL: RGlobal nLPHL One Working Group (GLOW) retrospective analyses. Blood advances,

Fløisand, Y., Brinch, L., Gedde-Dahl, T., Tjønnfjord, G. E., Dybedal, I., Holte, H., Heldal, D., Torfoss, D., ... Kolstad, A. (2012). Ultra-short course sirolimus contributes to effective GVHD prophylaxis after reduced-intensity allogeneic hematopoietic cell transplantation. Bone marrow transplantation, 47(12), 1552-7.

Fosså, A., Fiskvik, I. H., Kolstad, A., Lauritzsen, G. F., Aurlien, E., Blystad, A. K., Hole, K. H., Ikonomou, I. M., & Holte, H. (2012). Two escalated followed by six standard BEACOPP in advanced-stage high-risk classical Hodgkin lymphoma: high cure rates but increased risk of aseptic osteonecrosis. Annals of oncology, 23(5), 1254-9.

Fosså, A., Smeland, K., Fagerli, U. M., Galleberg, R. B., Bersvendsen, H. S., & Holte, H. (2020). Brentuximab vedotin in relapsed or refractory classical hodgkin lymphoma: real life experience in Norway 2011-2016. Acta oncologica, 59(1), 101-105.

Freeman, C. L., Savage, K. J., Villa, D. R., Scott, D. W., Srour, L., Gerrie, A. S., Brown, M. J., Slack, G. W., ... Sehn, L. H. (2021). Long-term results of PET-guided radiation in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP. Blood, 137(7), 929-938.

Frøen, H. M., Brodtkorb, M., Holte, H., Kolstad, A., Myhre, A. E., Remberger, M., Tjønnfjord, G. E., & Gedde-Dahl, T. (2025). Allogen stamcelletransplantasjon for pasienter med lymfom 2011–21. Tidsskrift for den Norske legeforening, 145(3)

Gallamini, A., Rossi, A., Patti, C., Picardi, M., Romano, A., Cantonetti, M., Oppi, S., Viviani, S., ... Rambaldi, A. (2020). Consolidation Radiotherapy Could Be Safely Omitted in Advanced Hodgkin Lymphoma With Large Nodal Mass in Complete Metabolic Response After ABVD: Final Analysis of the Randomized GITIL/FIL HD0607 Trial. Journal of clinical oncology, 38(33), 3905-3913.

Gang, A. O., Strøm, C., Pedersen, M., d'Amore, F., Pedersen, L. M., Bukh, A., Pedersen, B. B., Moeller, M. B., ... Nully Brown, P. d. (2012). R-CHOEP-14 improves overall survival in young high-risk patients with diffuse large B-cell lymphoma compared with R-CHOP-14. A population-based investigation from the Danish Lymphoma Group. Annals of oncology, 23(1), 147-53.

Garnock-Jones, K. P. (2013). Brentuximab vedotin: a review of its use in patients with hodgkin lymphoma and systemic anaplastic large cell lymphoma following previous treatment failure. Drugs, 73(4), 371-81.

Gavrilovic, I. T., Hormigo, A., Yahalom, J., DeAngelis, L. M., & Abrey, L. E. (2006). Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. Journal of clinical oncology, 24(28), 4570-4.

Geisler, C. H., Kolstad, A., Laurell, A., Andersen, N. S., Pedersen, L. B., Jerkeman, M., Eriksson, M., Nordstrom, M., ... Nordic Lymphoma Group (2008). Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood, 112(7), 2687-93.

Girbl, T., Lunzer, V., Greil, R., Namberger, K., & Hartmann, T. N. (2014). The CXCR4 and adhesion molecule expression of CD34+ hematopoietic cells mobilized by "on-demand" addition of plerixafor to granulocyte-colony-stimulating factor. Transfusion, 54(9), 2325-35.

Gisselbrecht, C., Glass, B., Mounier, N., Gill, D. S., Linch, D. C., Trneny, M., Bosly, A., Ketterer, N., ... Schmitz, N. (2010). Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era. Journal of clinical oncology, 28(27), 4184-4190.

Gjerstad, L., Skjeldal, O. H., Helseth, H. (2003). Nevrologi og nevrokirurgi: fra barn til voksen: undersøkelse, diagnose, behandling. Vett & viten.

Gleeson, M., Hawkes, E. A., Cunningham, D., Chadwick, N., Counsell, N., Lawrie, A., Jack, A., Smith, P., ... Linch, D. (2016). Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trial. British journal of haematology, 175(4), 668-672.

Glenny, A. M., Fernandez Mauleffinch, L. M., Pavitt, S., & Walsh, T. (2009). Interventions for the prevention and treatment of herpes simplex virus in patients being treated for cancer. Cochrane Database of Systematic Reviews, (1), CD006706.

Goldkuhl, C., Ekman, T., Wiklund, T., Telhaug, R., & Nordic Lymphoma Group (2002). Age-adjusted chemotherapy for primary central-nervous system lymphoma--a pilot study. Acta oncologica, 41(1), 29-35.

Gopal, A. K., Kahl, B. S., de Vos, S., Wagner-Johnston, N. D., Schuster, S. J., Jurczak, W. J., Flinn, I. W., Flowers, C. R., ... Salles, G. A. (2014). PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma. New England journal of medicine, 370(11), 1008-18.

Gospodarowicz, M. (2018). Personlig meddelelse

Gotti, M., Sciarra, R., Pulsoni, A., Merli, F., Luminari, S., Zerbi, C., Trentin, L., Re, A., ... Arcaini, L. (2023). Role of Rituximab Addition to First-line Chemotherapy Regimens in Nodular Lymphocyte-predominant Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi. HemaSphere, 7(4), e837.

Guadagnolo, B. A., Punglia, R. S., Kuntz, K. M., Mauch, P. M., & Ng, A. K. (2006). Cost-effectiveness analysis of computerized tomography in the routine follow-up of patients after primary treatment for Hodgkin's disease. Journal of clinical oncology, 24(25), 4116-22.

Haas, R. L., Poortmans, P., de Jong, D., Aleman, B. M., Dewit, L. G., Verheij, M., Hart, A. A., van Oers, M. H., ... Bartelink, H. (2003). High response rates and lasting remissions after low-dose involved field radiotherapy in indolent lymphomas. Journal of clinical oncology, 21(13), 2474-80.

Haas, R. L., Poortmans, P., de Jong, D., Verheij, M., van der Hulst, M., de Boer, J. P., & Bartelink, H. (2005). Effective palliation by low dose local radiotherapy for recurrent and/or chemotherapy refractory non-follicular lymphoma patients. European journal of cancer, 41(12), 1724-30.

Han, J. J., Kim, T. M., Jeon, Y. K., Kim, M. K., Khwarg, S. I., Kim, C. W., Kim, I. H., & Heo, D. S. (2015). Long-term outcomes of first-line treatment with doxycycline in patients with previously untreated ocular adnexal marginal zone B cell lymphoma. Annals of hematology, 94(4), 575-81.

Hans, C. P., Weisenburger, D. D., Greiner, T. C., Gascoyne, R. D., Delabie, J., Ott, G., Müller-Hermelink, H. K., Campo, E., ... Chan, W. C. (2004). Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood, 103(1), 275-82.

Hasenclever, D., & Diehl, V. (1998). A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. New England journal of medicine, 339(21), 1506-14.

Hermine, O., Hoster, E., Walewski, J., Bosly, A., Stilgenbauer, S., Thieblemont, C., Szymczyk, M., Bouabdallah, R., ... European Mantle Cell Lymphoma Network (2016). Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet, 388(10044), 565-75.

Herrera, A. F., LeBlanc, M., Castellino, S. M., Li, H., Rutherford, S. C., Evens, A. M., Davison, K., Punnett, A., ... Friedberg, J. W. (2024). Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma. New England journal of medicine, 391(15), 1379-1389.

Hertzberg, M., Grigg, A., Gottlieb, D., Szer, J., Roberts, A., Hoyt, R., Huang, G., & Bradstock, K. F. (2006). Reduced-intensity allogeneic haemopoietic stem cell transplantation induces durable responses in patients with chronic B-lymphoproliferative disorders. Bone marrow transplantation, 37(10), 923-8.

Hiddemann, W., Kneba, M., Dreyling, M., Schmitz, N., Lengfelder, E., Schmits, R., Reiser, M., Metzner, B., ... Unterhalt, M. (2005). Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood, 106(12), 3725-32.

Hill, Q. A., & Owen, R. G. (2006). CNS prophylaxis in lymphoma: who to target and what therapy to use. Blood reviews, 20(6), 319-32.

Hoelzer, D., Walewski, J., Dohner, H., Viardot, A., Hiddemann, W., Spiekermann, K., Serve, H., Duhrsen, U., ... German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia (2014). Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial. Blood, 124(26), 3870-9.

Holland, J. C., & Reznik, I. (2005). Pathways for psychosocial care of cancer survivors. Cancer, 104(11 Suppl), 2624-37.

Hollender, A., Kvaloy, S., Lote, K., Nome, O., & Holte, H. (2000). Prognostic factors in 140 adult patients with non-Hodgkin's lymphoma with systemic central nervous system (CNS) involvement. A single centre analysis. European journal of cancer, 36(14), 1762-8.

Holte, H., Leppä, S., Björkholm, M., Fluge, O., Jyrkkiö, S., Delabie, J., Sundström, C., Karjalainen-Lindsberg, M. L., ... Eriksson, M. (2013). Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study. Annals of oncology, 24(5), 1385-92.

Horwitz, S., O'Connor, O. A., Pro, B., Illidge, T., Fanale, M., Advani, R., Bartlett, N. L., Christensen, J. H., ... Trümper, L. (2019). Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet, 393(10168), 229-240.

Hoskin, P. J., Diez, P., Williams, M., Lucraft, H., Bayne, M., & Participants of the Lymphoma Radiotherapy, G. (2013). Recommendations for the use of radiotherapy in nodal lymphoma. Clinical oncology (Royal College of Radiologists), 25(1), 49-58.

Hoster, E., Dreyling, M., Klapper, W., Gisselbrecht, C., van Hoof, A., Kluin-Nelemans, H. C., Pfreundschuh, M., Reiser, M., ... European Mantle Cell Lymphoma Network (2008). A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood, 111(2), 558-65.

Hoster, E., Rosenwald, A., Berger, F., Bernd, H. W., Hartmann, S., Loddenkemper, C., Barth, T. F., Brousse, N., ... Klapper, W. (2016). Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network. Journal of clinical oncology, 34(12), 1386-94.

Hutchings, M., Morschhauser, F., Iacoboni, G., Carlo-Stella, C., Offner, F. C., Sureda, A., Salles, G., Martínez-Lopez, J., ... Dickinson, M. J. (2021). Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial. Journal of clinical oncology, 39(18), 1959-1970.

International Non-Hodgkin's Lymphoma Prognostic Factors Project (1993). A predictive model for aggressive non-Hodgkin's lymphoma. New England journal of medicine, 329(14), 987-94.

Jantunen, E., & Varmavuo, V. (2014). Plerixafor for mobilization of blood stem cells in autologous transplantation: an update. Expert opinion on biological therapy, 14(6), 851-61.

Johnson, N. A., Savage, K. J., Ludkovski, O., Ben-Neriah, S., Woods, R., Steidl, C., Dyer, M. J., Siebert, R., ... Horsman, D. E. (2009). Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood, 114(11), 2273-9.

Johnson, P., Federico, M., Kirkwood, A., Fosså, A., Berkahn, L., Carella, A., d'Amore, F., Enblad, G., ... Barrington, S. (2016). Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma. New England journal of medicine, 374(25), 2419-29.

Jones, G. W., Kacinski, B. M., Wilson, L. D., Willemze, R., Spittle, M., Hohenberg, G., Handl-Zeller, L., Trautinger, F., & Knobler, R. (2002). Total skin electron radiation in the management of mycosis fungoides: Consensus of the European Organization for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Project Group. Journal of the American Academy of Dermatology, 47(3), 364-370.

Juweid, M. E., & Cheson, B. D. (2005). Role of positron emission tomography in lymphoma. Journal of clinical oncology, 23(21), 4577-80.

Juweid, M. E., & Cheson, B. D. (2006). Positron-emission tomography and assessment of cancer therapy. New England journal of medicine, 354(5), 496-507.

Kahl, B. S., Hong, F., Williams, M. E., Gascoyne, R. D., Wagner, L. I., Krauss, J. C., Habermann, T. M., Swinnen, L. J., ... Horning, S. J. (2014). Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402. Journal of clinical oncology, 32(28), 3096-102.

Kamdar, M., Solomon, S. R., Arnason, J., Johnston, P. B., Glass, B., Bachanova, V., Ibrahimi, S., Mielke, S., ... Abramson, J. S. (2022). Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet, 399(10343), 2294-2308.

Kamstrup, M. R., Gniadecki, R., Iversen, L., Skov, L., Petersen, P. M., Loft, A., & Specht, L. (2015). Low-dose (10-Gy) total skin electron beam therapy for cutaneous T-cell lymphoma: an open clinical study and pooled data analysis. International journal of radiation oncology, biology, physics, 92(1), 138-43.

Kansara, R., Villa, D., Gerrie, A. S., Klasa, R., Shenkier, T., Scott, D. W., Slack, G. W., Gascoyne, R. D., ... Savage, K. J. (2017). Site of central nervous system (CNS) relapse in patients with diffuse large B-cell lymphoma (DLBCL) by the CNS-IPI risk model. British journal of haematology, 179(3), 508-510.

Kaplan, L. D., Lee, J. Y., Ambinder, R. F., Sparano, J. A., Cesarman, E., Chadburn, A., Levine, A. M., & Scadden, D. T. (2005). Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood, 106(5), 1538-43.

Kasenda, B., Loeffler, J., Illerhaus, G., Ferreri, A. J. M., Rubenstein, J., & Batchelor, T. T. (2016). The role of whole brain radiation in primary CNS lymphoma. Blood, 128(1), 32-36.

Kasenda, B., Schorb, E., Fritsch, K., Finke, J., & Illerhaus, G. (2012). Prognosis after high-dose chemotherapy followed by autologous stem-cell transplantation as first-line treatment in primary CNS lymphoma--a long-term follow-up study. Annals of oncology, 23(10), 2670-5.

Kharazmi, E., Fallah, M., Pukkala, E., Olsen, J. H., Tryggvadottir, L., Sundquist, K., Tretli, S., & Hemminki, K. (2015). Risk of familial classical Hodgkin lymphoma by relationship, histology, age, and sex: a joint study from five Nordic countries. Blood, 126(17), 1990-5.

Khouri, I. F., Lee, M. S., Saliba, R. M., Jun, G., Fayad, L., Younes, A., Pro, B., Acholonu, S., ... Champlin, R. E. (2003). Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma. Journal of clinical oncology, 21(23), 4407-12.

Kim, Y. H., Bagot, M., Pinter-Brown, L., Rook, A. H., Porcu, P., Horwitz, S. M., Whittaker, S., Tokura, Y., ... Duvic, M. (2018). Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. The Lancet. Oncology, 19(9), 1192-1204.

Kim, Y. H., Tavallaee, M., Sundram, U., Salva, K. A., Wood, G. S., Li, S., Rozati, S., Nagpal, S., ... Horwitz, S. M. (2015). Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sezary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project. Journal of clinical oncology, 33(32), 3750-8.

Kim, Y. H., Willemze, R., Pimpinelli, N., Whittaker, S., Olsen, E. A., Ranki, A., Dummer, R., & Hoppe, R. T. (2007). TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood, 110(2), 479-84.

Kimby, E., Ostenstad, B., Brown, P., Hagberg, H., Erlanson, M., Holte, H., Linden, O., Johansson, A. S., ... Nordic Lymphoma Group (2015). Two courses of four weekly infusions of rituximab with or without interferon-alpha2a: final results from a randomized phase III study in symptomatic indolent B-cell lymphomas. Leukemia & lymphoma, 56(9), 2598-607.

Kluin-Nelemans, H. C., Hoster, E., Hermine, O., Walewski, J., Geisler, C. H., Trneny, M., Stilgenbauer, S., Kaiser, F., ... Dreyling, M. H. (2020). Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial. Journal of clinical oncology, 38(3), 248-256.

Knols, R., Aaronson, N. K., Uebelhart, D., Fransen, J., & Aufdemkampe, G. (2005). Physical exercise in cancer patients during and after medical treatment: a systematic review of randomized and controlled clinical trials. Journal of clinical oncology, 23(16), 3830-42.

Kobe, C., Dietlein, M., Franklin, J., Markova, J., Lohri, A., Amthauer, H., Klutmann, S., Knapp, W. H., ... Engert, A. (2008). Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. Blood, 112(10), 3989-94.

Koch, P., Grothaus-Pinke, B., Hiddemann, W., Willich, N., Reers, B., del Valle, F., Bodenstein, H., Pfreundschuh, M., ... Tiemann, M. (1997). Primary lymphoma of the stomach: three-year results of a prospective multicenter study. The German Multicenter Study Group on GI-NHL. Annals of oncology, 8(Suppl 1), 85-8.

Kolstad, A., Holte, H., Fosså, A., Lauritzsen, G. F., Gaustad, P., & Torfoss, D. (2007). Pneumocystis jirovecii pneumonia in B-cell lymphoma patients treated with the rituximab-CHOEP-14 regimen. Haematologica, 92(1), 139-40.

Kolstad, A., Laurell, A., Jerkeman, M., Gronbaek, K., Elonen, E., Raty, R., Pedersen, L. B., Loft, A., ... Nordic Lymphoma Group (2014). Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma. Blood, 123(19), 2953-9.

Kolstad, A., Nome, O., Delabie, J., Lauritzsen, G. F., Fossa, A., & Holte, H. (2007). Standard CHOP-21 as first line therapy for elderly patients with Hodgkin's lymphoma. Leukemia & lymphoma, 48(3), 570-6.

Korfel, A., Thiel, E., Martus, P., Mohle, R., Griesinger, F., Rauch, M., Roth, A., Hertenstein, B., ... Weller, M. (2015). Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma. Neurology, 84(12), 1242-8.

Kristinsson, S. Y., Goldin, L. R., Björkholm, M., Koshiol, J., Turesson, I., & Landgren, O. (2009). Genetic and immune-related factors in the pathogenesis of lymphoproliferative and plasma cell malignancies. Haematologica, 94(11), 1581-9.

Kusumi, E., Kami, M., Kanda, Y., Murashige, N., Kishi, Y., Suzuki, R., Takeuchi, K., Tanimoto, T. E., ... Takaue, Y. (2005). Reduced-intensity hematopoietic stem-cell transplantation for malignant lymphoma: a retrospective survey of 112 adult patients in Japan. Bone marrow transplantation, 36(3), 205-13.

Kwong, Y. L., Kim, W. S., Lim, S. T., Kim, S. J., Tang, T., Tse, E., Leung, A. Y., & Chim, C. S. (2012). SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group. Blood, 120(15), 2973-80.

Lagerlöf, I., Holte, H., Glimelius, I., Björkholm, M., Enblad, G., Erlanson, M., Fluge, Ø., Fohlin, H., ... Molin, D. (2020). No excess long-term mortality in stage I-IIA Hodgkin lymphoma patients treated with ABVD and limited field radiotherapy. British journal of haematology, 188(5), 685-691.

Lambertini, M., Peccatori, F. A., Demeestere, I., Amant, F., Wyns, C., Stukenborg, J. B., Paluch-Shimon, S., Halaska, M. J., ... Jordan, K. (2020). Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guidelines(†). Annals of oncology, 31(12), 1664-1678.

Larsen, I. K. (2025). Cancer in Norway 2024: cancer incidence, mortality, survival and prevalence in Norway. Norwegian Institute of Public Health, Cancer Registry of Norway.

Larsen, I. K., Aagnes, B., Breivik, S., Hestad, J. J., Jakobsen, E., Johannesen, T. B., ... Lambert, P. C. (2026). Cancer in Norway 2025: cancer incidence, mortality, survival and prevalence in Norway Oslo: Norwegian Institute of Public Health, Cancer Registry of Norway. Hentet fra https://www.fhi.no/Content/cancer-in-norway-2025.pdf

Le Gouill, S., Thieblemont, C., Oberic, L., Moreau, A., Bouabdallah, K., Dartigeas, C., Damaj, G., Gastinne, T., ... Lysa Group (2017). Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma. New England journal of medicine, 377(13), 1250-1260.

Lekovich, J., Lobel, A. L. S., Stewart, J. D., Pereira, N., Kligman, I., & Rosenwaks, Z. (2016). Female patients with lymphoma demonstrate diminished ovarian reserve even before initiation of chemotherapy when compared with healthy controls and patients with other malignancies. Journal of assisted reproduction and genetics, 33(5), 657-662.

Lenz, G., Dreyling, M., Hoster, E., Wormann, B., Duhrsen, U., Metzner, B., Eimermacher, H., Neubauer, A., ... Hiddemann, W. (2005). Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). Journal of clinical oncology, 23(9), 1984-92.

Leonard, J. P., Trneny, M., Izutsu, K., Fowler, N. H., Hong, X., Zhu, J., Zhang, H., Offner, F., ... Gribben, J. G. (2019). AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma. Journal of clinical oncology, 37(14), 1188-1199.

Leppä, S., Jørgensen, J., Tierens, A., Meriranta, L., Østlie, I., de Nully Brown, P., Fagerli, U. M., Larsen, T. S., ... Holte, H. (2020). Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis. Blood advances, 4(9), 1906-1915.

Leppä, S., Jørgensen, J. M., Karjalainen-Lindsberg, M., Beiske, K., Pedersen, M., Drott, K., Pasanen, A., Karihtala, K., ... Holte, H. (2022). Biomarker-Driven Treatment Strategy in High-Risk Large B-Cell Lymphoma: Final Results of a Nordic Phase 2 Study. Blood, 140(Suppl 1), 1768-1769.

Leppä, S., Meriranta, L., Arffman, M., Jørgensen, J., Karjalainen-Lindsberg, M. L., Beiske, K., Pedersen, M., Drott, K., ... Holte, H. (2025). Biomarker-adapted treatment in high-risk large B-cell lymphoma. HemaSphere, 9(5), e70139.

Levernes, S., Johannessen, D. C. (2003). Volum og doser ved strålebehandling: definisjoner, retningslinjer for bruk, dokumentasjon og rapportering (StrålevernRapport 2003:12). Østerås: Statens strålevern. Hentet fra https://dsa.no/publikasjoner/stralevernrapport-12-2003-volum-og-doser-ved-stralebehandling/straalevernrapport-2003-12-volum-og-doser-ved-straalebehandling-definisjoner-retningslinjer-dokumentasjon-rapportering.pdf

Lewis, D. J., Jerkeman, M., Sorrell, L., Wright, D., Glimelius, I., Poulsen, C. B., Pasanen, A., Rawstron, A., ... Rule, S. (2025). Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH): a randomised, open-label, phase 2/3 superiority trial. Lancet, 406(10514), 1953-1968.

Lewis, K. L., Jakobsen, L. H., Villa, D., Smedby, K. E., Savage, K. J., Eyre, T. A., Cwynarski, K., Bishton, M. J., ... Cheah, C. Y. (2023). High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma. Journal of clinical oncology, 41(35), 5376-5387.

Lin, T. L., Kuo, M. C., Shih, L. Y., Dunn, P., Wang, P. N., Wu, J. H., Tang, T. C., Chang, H., ... Lu, S. C. (2012). Value of surveillance computed tomography in the follow-up of diffuse large B-cell and follicular lymphomas. Annals of hematology, 91(11), 1741-5.

Linch, D. C., Winfield, D., Goldstone, A. H., Moir, D., Hancock, B., McMillan, A., Chopra, R., Milligan, D., & Hudson, G. V. (1993). Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet, 341(8852), 1051-4.

Linton, K. M., Vitolo, U., Jurczak, W., Lugtenburg, P. J., Gyan, E., Sureda, A., Christensen, J. H., Hess, B., ... Vose, J. M. (2024). Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study. The Lancet. Haematology, 11(8), e593-e605.

Lister, T. A., Crowther, D., Sutcliffe, S. B., Glatstein, E., Canellos, G. P., Young, R. C., Rosenberg, S. A., Coltman, C. A., & Tubiana, M. (1989). Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. Journal of clinical oncology, 7(11), 1630-6.

Liu, H., Ye, H., Ruskone-Fourmestraux, A., De Jong, D., Pileri, S., Thiede, C., Lavergne, A., Boot, H., ... Du, M. Q. (2002). T(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication. Gastroenterology, 122(5), 1286-94.

Ljungman, P., Cordonnier, C., Einsele, H., Englund, J., Machado, C. M., Storek, J., & Small, T. (2009). Vaccination of hematopoietic cell transplant recipients. Bone marrow transplantation, 44(8), 521-6.

Locke, F. L., Miklos, D. B., Jacobson, C. A., Perales, M. A., Kersten, M. J., Oluwole, O. O., Ghobadi, A., Rapoport, A. P., ... Westin, J. R. (2022). Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. New England journal of medicine, 386(7), 640-654.

Lofthus, A. S., & Allen, S. M. (2006). Kan transkutan elektrisk nervestimulering lindre nevropatisk smerte?. Fysioterapeuten, 73(4), 16-25.

Loge, J. H., Abrahamsen, A. F., Ekeberg, O., & Kaasa, S. (1999). Hodgkin's disease survivors more fatigued than the general population. Journal of clinical oncology, 17(1), 253-61.

Lok, A. S. F., Bonis, P. A. L. (18. desember 2017). Hepatitis B virus reactivation associated with immunosuppressive therapy. [database]. Waltham, MA: UpToDate, Inc.. Hentet 10. desember 2018

Lote, K., Holte, H., Nome, O., Langholm, R., & Kvaløy, S. (2000). Stage I high-grade non-Hodgkin's lymphoma. Acta oncologica, 39(7), 865-72.

Lowry, L., Smith, P., Qian, W., Falk, S., Benstead, K., Illidge, T., Linch, D., Robinson, M., ... Hoskin, P. (2011). Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial. Radiotherapy and oncology, 100(1), 86-92.

Luminari, S., Fossa, A., Trotman, J., Molin, D., d'Amore, F., Enblad, G., Berkahn, L., Barrington, S. F., ... Johnson, P. W. M. (2024). Long-Term Follow-Up of the Response-Adjusted Therapy for Advanced Hodgkin Lymphoma Trial. Journal of clinical oncology, 42(1), 13-18.

Mahadeo, K. M., Baiocchi, R., Beitinjaneh, A., Chaganti, S., Choquet, S., Dierickx, D., Dinavahi, R., Duan, X., ... Prockop, S. (2024). Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial. The Lancet. Oncology, 25(3), 376-387.

Marcus, R., Davies, A., Ando, K., Klapper, W., Opat, S., Owen, C., Phillips, E., Sangha, R., ... Hiddemann, W. (2017). Obinutuzumab for the First-Line Treatment of Follicular Lymphoma. New England journal of medicine, 377(14), 1331-1344.

Maris, M. B., Sandmaier, B. M., Storer, B. E., Chauncey, T., Stuart, M. J., Maziarz, R. T., Agura, E., Langston, A. A., ... Maloney, D. G. (2004). Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood, 104(12), 3535-42.

Martelli, M., Ceriani, L., Ciccone, G., Ricardi, U., Kriachok, I., Botto, B., Balzarotti, M., Tucci, A., ... Zucca, E. (2024). Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial Results. Journal of clinical oncology, 42(34), 4071-4083.

Martinelli, G., Schmitz, S. F., Utiger, U., Cerny, T., Hess, U., Bassi, S., Okkinga, E., Stupp, R., ... Ghielmini, M. (2010). Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. Journal of clinical oncology, 28(29), 4480-4.

Mauch, P. (2001). Follicular non-Hodgkin's lymphoma: the role of radiation therapy. Annals of hematology, 80(Suppl 3), B63-5.

Mehra, T., Ikenberg, K., Moos, R. M., Benz, R., Nair, G., Schanz, U., Haralambieva, E., Hoetzenecker, W., ... Cozzio, A. (2015). Brentuximab as a treatment for CD30+ mycosis fungoides and Sezary syndrome. JAMA dermatology, 151(1), 73-7.

Meissner, J., Tichy, D., Dietrich, S., Schmitt, T., Ziepert, M., Kuhnt, E., Rixecker, T., Witzens-Harig, M., ... Ho, A. D. (2014). Parenthood in long-term survivors after CHOP with or without etoposide treatment for aggressive lymphoma. British journal of haematology, 166(4), 612-5.

Meissner, J., Tichy, D., Katzke, V., Kühn, T., Dietrich, S., Schmitt, T., Ziepert, M., Kuhnt, E., ... Ho, A. D. (2015). Long-term ovarian function in women treated with CHOP or CHOP plus etoposide for aggressive lymphoma. Annals of oncology, 26(8), 1771-6.

Melani, C., Advani, R., Roschewski, M., Walters, K. M., Chen, C. C., Baratto, L., Ahlman, M. A., Miljkovic, M. D., ... Wilson, W. H. (2018). End-of-treatment and serial PET imaging in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R: a paradigm shift in clinical decision making. Haematologica, 103(8), 1337-1344.

Melchers, R. C., Willemze, R., Daniëls, L. A., Neelis, K. J., Bekkenk, M. W., de Haas, E. R. M., Horvath, B., van Rossum, M. M., ... Quint, K. D. (2017). Recommendations for the Optimal Radiation Dose in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma: A Report of the Dutch Cutaneous Lymphoma Group. International journal of radiation oncology, biology, physics, 99(5), 1279-1285.

Melsack, R., Wall, P. D. E. (1999). Textbook of pain. Churchill Livingstone.

Morris, E., Thomson, K., Craddock, C., Mahendra, P., Milligan, D., Cook, G., Smith, G. M., Parker, A., ... Mackinnon, S. (2004). Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood, 104(13), 3865-71.

Morris, P. G., Correa, D. D., Yahalom, J., Raizer, J. J., Schiff, D., Grant, B., Grimm, S., Lai, R. K., ... Omuro, A. (2013). Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. Journal of clinical oncology, 31(31), 3971-9.

Morschhauser, F., Fowler, N. H., Feugier, P., Bouabdallah, R., Tilly, H., Palomba, M. L., Fruchart, C., Libby, E. N., ... Salles, G. A. (2018). Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma. New England journal of medicine, 379(10), 934-947.

Moskowitz, A. J., Lunning, M. A., & Horwitz, S. M. (2014). How I treat the peripheral T-cell lymphomas. Blood, 123(17), 2636-44.

Moskowitz, A. J., Shah, G., Schöder, H., Ganesan, N., Drill, E., Hancock, H., Davey, T., Perez, L., ... Moskowitz, C. H. (2021). Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma. Journal of clinical oncology, 39(28), 3109-3117.

Moskowitz, C. H., Nademanee, A., Masszi, T., Agura, E., Holowiecki, J., Abidi, M. H., Chen, A. I., Stiff, P., ... Aethera Study Group (2015). Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, 385(9980), 1853-62.

Mounier, N., El Gnaoui, T., Tilly, H., Canioni, D., Sebban, C., Casasnovas, R. O., Delarue, R., Sonet, A., ... Haioun, C. (2013). Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial. Haematologica, 98(11), 1726-31.

Mounier, N., Spina, M., Gabarre, J., Raphael, M., Rizzardini, G., Golfier, J. B., Vaccher, E., Carbone, A., ... Gisselbrecht, C. (2006). AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy. Blood, 107(10), 3832-40.

Nakamura, S., Ye, H., Bacon, C. M., Goatly, A., Liu, H., Banham, A. H., Ventura, R., Matsumoto, T., ... Du, M. Q. (2007). Clinical impact of genetic aberrations in gastric MALT lymphoma: a comprehensive analysis using interphase fluorescence in situ hybridisation. Gut, 56(10), 1358-63.

Neelapu, S. S., Chavez, J. C., Sehgal, A. R., Epperla, N., Ulrickson, M. L., Bachy, E., Munshi, P. N., Casulo, C., ... Jacobson, C. A. (2025). Five-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma. Journal of clinical oncology, 43(33), 3573-3577.

Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., ... Go, W. Y. (2017). Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. New England journal of medicine, 377(26), 2531-2544.

Northend, M., Wilson, W., Ediriwickrema, K., Clifton-Hadley, L., Qian, W., Rana, Z., Martin, T. L., Townsend, W., ... Ardeshna, K. M. (2025). Early rituximab monotherapy versus watchful waiting for advanced stage, asymptomatic, low tumour burden follicular lymphoma: long-term results of a randomised, phase 3 trial. The Lancet. Haematology, 12(5), e335-e345.

Ohkubo, Y., Saito, Y., Ushijima, H., Onishi, M., Kazumoto, T., Saitoh, J. I., Kubota, N., Kobayashi, H., ... Kurosumi, M. (2017). Radiotherapy for localized gastric mucosa-associated lymphoid tissue lymphoma: long-term outcomes over 10 years. Journal of radiation research, 58(4), 537-542.

Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982). Toxicity and response criteria of the Eastern Cooperative Oncology Group. American journal of clinical oncology, 5(6), 649-55.

Oktay, K., Harvey, B. E., Partridge, A. H., Quinn, G. P., Reinecke, J., Taylor, H. S., Wallace, W. H., Wang, E. T., & Loren, A. W. (2018). Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update. Journal of clinical oncology, 36(19), 1994-2001.

Omuro, A., Correa, D. D., DeAngelis, L. M., Moskowitz, C. H., Matasar, M. J., Kaley, T. J., Gavrilovic, I. T., Nolan, C., ... Sauter, C. S. (2015). R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. Blood, 125(9), 1403-10.

Omuro, A. M. P., DeAngelis, L. M., Karrison, T., Bovi, J. A., Rosenblum, M., Corn, B. W., Correa, D., Wefel, J. S., ... NRG (2020). Randomized phase II study of rituximab, methotrexate (MTX), procarbazine, vincristine, and cytarabine (R-MPV-A) with and without low-dose whole-brain radiotherapy (LD-WBRT) for newly diagnosed primary CNS lymphoma (PCNSL). Journal of clinical oncology, 38(15_suppl), 2501-2501.

Opat, S., Tedeschi, A., Linton, K., McKay, P., Hu, B., Chan, H., Jin, J., Sobieraj-Teague, M., ... Trotman, J. (2021). The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma. Clinical cancer research, 27(23), 6323-6332.

Övergaard, N., Lia, K., Collin, J., Asdahl, P. H., Wikman, P., Glimelius, I., Lagerlof, I., Johansson, A. S., ... Molin, D. (2026). AVD is an effective chemotherapy backbone in first-line treatment of older patients with classical Hodgkin lymphoma. Blood advances, Apr 1, Epub ahead of print.

Ozsahin, M., Tsang, R. W., Poortmans, P., Belkacémi, Y., Bolla, M., Dincbas, F. O., Landmann, C., Castelain, B., ... Zouhair, A. (2006). Outcomes and patterns of failure in solitary plasmacytoma: a multicenter Rare Cancer Network study of 258 patients. International journal of radiation oncology, biology, physics, 64(1), 210-7.

Palmer, A. C., Kurtz, D. M., & Alizadeh, A. A. (2023). Cell-of-Origin Subtypes and Therapeutic Benefit from Polatuzumab Vedotin. New England journal of medicine, 389(8), 764-766.

Peyrade, F., Jardin, F., Thieblemont, C., Thyss, A., Emile, J. F., Castaigne, S., Coiffier, B., Haioun, C., ... Groupe d'Etude des Lymphomes de l'Adulte investigators (2011). Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. The Lancet. Oncology, 12(5), 460-8.

Pfreundschuh, M. (2005). Mature T-cell and NK/T-cell neoplasms. Clinical advances in hematology & oncology : H&O, 3(11), suppl 8-9.

Pfreundschuh, M., Kuhnt, E., Trümper, L., Osterborg, A., Trneny, M., Shepherd, L., Gill, D. S., Walewski, J., ... Murawski, N. (2011). CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. The Lancet. Oncology, 12(11), 1013-22.

Pfreundschuh, M., Trumper, L., Kloess, M., Schmits, R., Feller, A. C., Rube, C., Rudolph, C., Reiser, M., ... German High-Grade Non-Hodgkin's Lymphoma Study Group (2004). Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood, 104(3), 634-41.

Pfreundschuh, M., Trumper, L., Kloess, M., Schmits, R., Feller, A. C., Rudolph, C., Reiser, M., Hossfeld, D. K., ... German High-Grade Non-Hodgkin's Lymphoma Study Group (2004). Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood, 104(3), 626-33.

Philip, T., Guglielmi, C., Hagenbeek, A., Somers, R., Van der Lelie, H., Bron, D., Sonneveld, P., Gisselbrecht, C., ... Chauvin, F. (1995). Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. New England journal of medicine, 333(23), 1540-5.

Poeschel, V., Held, G., Ziepert, M., Witzens-Harig, M., Holte, H., Thurner, L., Borchmann, P., Viardot, A., ... German Lymphoma Alliance (2020). Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. Lancet, 394(10216), 2271-2281.

Prince, H. M., Kim, Y. H., Horwitz, S. M., Dummer, R., Scarisbrick, J., Quaglino, P., Zinzani, P. L., Wolter, P., ... Alcanza study group (2017). Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet, 390(10094), 555-566.

Pro, B., Advani, R., Brice, P., Bartlett, N. L., Rosenblatt, J. D., Illidge, T., Matous, J., Ramchandren, R., ... Shustov, A. (2012). Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. Journal of clinical oncology, 30(18), 2190-6.

Pulczynski, E. J., Kuittinen, O., Erlanson, M., Hagberg, H., Fosså, A., Eriksson, M., Nordstrøm, M., Ostenstad, B., ... Fagerli, U. M. (2015). Successful change of treatment strategy in elderly patients with primary central nervous system lymphoma by de-escalating induction and introducing temozolomide maintenance: results from a phase II study by the Nordic Lymphoma Group. Haematologica, 100(4), 534-40.

Quasthoff, S., & Hartung, H. P. (2002). Chemotherapy-induced peripheral neuropathy. Journal of neurology, 249(1), 9-17.

Roddie, C., Neill, L., Osborne, W., Iyengar, S., Tholouli, E., Irvine, D., Chaganti, S., Besley, C., ... Kuhnl, A. (2023). Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma. Blood advances, 7(12), 2872-2883.

Rummel, M. J., Niederle, N., Maschmeyer, G., Banat, G. A., von Grunhagen, U., Losem, C., Kofahl-Krause, D., Heil, G., ... Study group indolent Lymphomas (2013). Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet, 381(9873), 1203-10.

Rutherford, S. C., Li, H., Herrera, A. F., LeBlanc, M., Ahmed, S., Davison, K., Parsons, S. K., Unger, J. M., ... Evens, A. M. (2025). Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826. Journal of clinical oncology, 43(27), 2968-2973.

Salles, G., Duell, J., González Barca, E., Tournilhac, O., Jurczak, W., Liberati, A. M., Nagy, Z., Obr, A., ... Maddocks, K. (2020). Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. The Lancet. Oncology, 21(7), 978-988.

Salles, G., Seymour, J. F., Offner, F., Lopez-Guillermo, A., Belada, D., Xerri, L., Feugier, P., Bouabdallah, R., ... Tilly, H. (2011). Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet, 377(9759), 42-51.

Santarsieri, A., Mitchell, E., Pham, M. H., Sanghvi, R., Jablonski, J., Lee-Six, H., Sturgess, K., Brice, P., ... Follows, G. A. (2025). The genomic and clinical consequences of replacing procarbazine with dacarbazine in escalated BEACOPP for Hodgkin lymphoma: a retrospective, observational study. The Lancet. Oncology, 26(1), 98-109.

Santoro, A., Magagnoli, M., Spina, M., Pinotti, G., Siracusano, L., Michieli, M., Nozza, A., Sarina, B., ... Balzarotti, M. (2007). Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma. Haematologica, 92(1), 35-41.

Savage, K. J., Johnson, N. A., Ben-Neriah, S., Connors, J. M., Sehn, L. H., Farinha, P., Horsman, D. E., & Gascoyne, R. D. (2009). MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood, 114(17), 3533-7.

Savage, K. J., Skinnider, B., Al-Mansour, M., Sehn, L. H., Gascoyne, R. D., & Connors, J. M. (2011). Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome. Blood, 118(17), 4585-90.

Schmitz, N., Pfistner, B., Sextro, M., Sieber, M., Carella, A. M., Haenel, M., Boissevain, F., Zschaber, R., ... Marrow, T. (2002). Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet, 359(9323), 2065-71.

Schmitz, N., Zeynalova, S., Nickelsen, M., Kansara, R., Villa, D., Sehn, L. H., Glass, B., Scott, D. W., ... Savage, K. J. (2016). CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP. Journal of clinical oncology, 34(26), 3150-6.

Schouten, H. C., Qian, W., Kvaloy, S., Porcellini, A., Hagberg, H., Johnsen, H. E., Doorduijn, J. K., Sydes, M. R., & Kvalheim, G. (2003). High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. Journal of clinical oncology, 21(21), 3918-27.

Schulz, H., Rehwald, U., Morschhauser, F., Elter, T., Driessen, C., Rudiger, T., Borchmann, P., Schnell, R., ... Reiser, M. (2008). Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood, 111(1), 109-11.

Schüring, A. N., Fehm, T., Behringer, K., Goeckenjan, M., Wimberger, P., Henes, M., Henes, J., Fey, M. F., & von Wolff, M. (2018). Practical recommendations for fertility preservation in women by the FertiPROTEKT network. Part I: Indications for fertility preservation. Archives of gynecology and obstetrics, 297(1), 241-255.

Schuster, S. J., Bishop, M. R., Tam, C. S., Waller, E. K., Borchmann, P., McGuirk, J. P., Jäger, U., Jaglowski, S., ... Maziarz, R. T. (2018). Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. New England journal of medicine, 380(1), 45-56.

Sehn, L. H., Bartlett, N. L., Matasar, M. J., Schuster, S. J., Assouline, S. E., Giri, P., Kuruvilla, J., Shadman, M., ... Budde, L. E. (2025). Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies. Blood, 145(7), 708-719.

Sehn, L. H., Berry, B., Chhanabhai, M., Fitzgerald, C., Gill, K., Hoskins, P., Klasa, R., Savage, K. J., ... Connors, J. M. (2007). The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood, 109(5), 1857-61.

Sehn, L. H., Chua, N., Mayer, J., Dueck, G., Trneny, M., Bouabdallah, K., Fowler, N., Delwail, V., ... Cheson, B. D. (2016). Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. The Lancet. Oncology, 17(8), 1081-1093.

Sehn, L. H., Herrera, A. F., Flowers, C. R., Kamdar, M. K., McMillan, A., Hertzberg, M., Assouline, S., Kim, T. M., ... Matasar, M. J. (2020). Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Journal of clinical oncology, 38(2), 155-165.

Shah, G. D., Yahalom, J., Correa, D. D., Lai, R. K., Raizer, J. J., Schiff, D., LaRocca, R., Grant, B., ... Abrey, L. E. (2007). Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. Journal of clinical oncology, 25(30), 4730-5.

Shimada, K., Yamaguchi, M., Atsuta, Y., Matsue, K., Sato, K., Kusumoto, S., Nagai, H., Takizawa, J., ... Kinoshita, T. (2020). Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): a multicentre, single-arm, phase 2 trial. The Lancet. Oncology, 21(4), 593-602.

Smeland, S., Blystad, A. K., Kvaløy, S. O., Ikonomou, I. M., Delabie, J., Kvalheim, G., Hammerstrom, J., Lauritzsen, G. F., & Holte, H. (2004). Treatment of Burkitt's/Burkitt-like lymphoma in adolescents and adults: a 20-year experience from the Norwegian Radium Hospital with the use of three successive regimens. Annals of oncology, 15(7), 1072-8.

Solal-Celigny, P., Roy, P., Colombat, P., White, J., Armitage, J. O., Arranz-Saez, R., Au, W. Y., Bellei, M., ... Montserrat, E. (2004). Follicular lymphoma international prognostic index. Blood, 104(5), 1258-65.

Soutar, R., Lucraft, H., Jackson, G., Reece, A., Bird, J., Low, E., Samson, D., Guidelines Working Group of the, U. K. M. F., ... British Society for Haematology (2004). Guidelines on the diagnosis and management of solitary plasmacytoma of bone and solitary extramedullary plasmacytoma. British journal of haematology, 124(6), 717-26.

Sparano, J. A. (2007). HIV-associated lymphoma: the evidence for treating aggressively but with caution. Current opinion in oncology, 19(5), 458-63.

Specht, L., Dabaja, B., Illidge, T., Wilson, L. D., & Hoppe, R. T. (2015). Modern radiation therapy for primary cutaneous lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group. International journal of radiation oncology, biology, physics, 92(1), 32-9.

Stein, H., Foss, H. D., Durkop, H., Marafioti, T., Delsol, G., Pulford, K., Pileri, S., & Falini, B. (2000). CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood, 96(12), 3681-95.

Suarez, F., Lortholary, O., Hermine, O., & Lecuit, M. (2006). Infection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation. Blood, 107(8), 3034-44.

Sureda, A., Corbacioglu, S., Greco, R., Kröger, N., Carreras, E. (2024). The EBMT Handbook: Hematopoietic Cell Transplantation and Cellular Therapies. Springer.

Sureda, A., Robinson, S., Canals, C., Carella, A. M., Boogaerts, M. A., Caballero, D., Hunter, A. E., Kanz, L., ... Schmitz, N. (2008). Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Journal of clinical oncology, 26(3), 455-62.

Sweetenham, J. W., Santini, G., Qian, W., Guelfi, M., Schmitz, N., Simnett, S., Nagler, A., Holte, H., ... Goldstone, A. H. (2001). High-dose therapy and autologous stem-cell transplantation versus conventional-dose consolidation/maintenance therapy as postremission therapy for adult patients with lymphoblastic lymphoma: results of a randomized trial of the European Group for Blood and Marrow Transplantation and the United Kingdom Lymphoma Group. Journal of clinical oncology, 19(11), 2927-36.

Swerdlow, S. H., Campo, E., Harris, N. L., Jaffe, E. S., Pileri, S. A., Stein, H., Thiele, J. (2017). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC.

Swerdlow, S. H., Campo, E., Pileri, S. A., Harris, N. L., Stein, H., Siebert, R., Advani, R., Ghielmini, M., ... Jaffe, E. S. (2016). The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood, 127(20), 2375-90.

Thieblemont, C., & Coiffier, B. (2006). Management of marginal zone lymphomas. Current treatment options in oncology, 7(3), 213-22.

Thieblemont, C., & Zucca, E. (2017). Clinical aspects and therapy of gastrointestinal MALT lymphoma. Best practice & research. Clinical haematology, 30(1-2), 109-117.

Tian, X. P., Cai, J., Xia, Y., Zhang, Y. C., Wang, L., Liu, P. P., Huang, H. Q., Li, Y. J., ... Cai, Q. Q. (2024). First-line sintilimab with pegaspargase, gemcitabine, and oxaliplatin in advanced extranodal natural killer/T cell lymphoma (SPIRIT): a multicentre, single-arm, phase 2 trial. The Lancet. Haematology, 11(5), e336-e344.

Tilly, H., Morschhauser, F., Sehn, L. H., Friedberg, J. W., Sharman, J. P., Herbaux, C., Burke, J. M., Matasar, M., ... Salles, G. (2022). Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. New England journal of medicine, 386(4), 351-363.

Trautinger, F., Knobler, R., Willemze, R., Peris, K., Stadler, R., Laroche, L., D'Incan, M., Ranki, A., ... Whittaker, S. (2006). EORTC consensus recommendations for the treatment of mycosis fungoides/Sezary syndrome. European journal of cancer, 42(8), 1014-30.

Tsang, R. W., Campbell, B. A., Goda, J. S., Kelsey, C. R., Kirova, Y. M., Parikh, R. R., Ng, A. K., Ricardi, U., ... Yahalom, J. (2018). Radiation Therapy for Solitary Plasmacytoma and Multiple Myeloma: Guidelines From the International Lymphoma Radiation Oncology Group. International journal of radiation oncology, biology, physics, 101(4), 794-808.

Tsang, R. W., & Gospodarowicz, M. K. (2007). Low-grade non-hodgkin lymphomas. Seminars in radiation oncology, 17(3), 198-205.

Tsimberidou, A. M., Catovsky, D., Schlette, E., O'Brien, S., Wierda, W. G., Kantarjian, H., Garcia-Manero, G., Wen, S., ... Keating, M. J. (2006). Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone. Cancer, 107(1), 125-35.

Van Besien, K. (2006). The evolving role of autologous and allogeneic stem cell transplantation in follicular lymphoma. Blood reviews, 20(5), 235-44.

van Oers, M. H., Klasa, R., Marcus, R. E., Wolf, M., Kimby, E., Gascoyne, R. D., Jack, A., Van't Veer, M., ... Hagenbeek, A. (2006). Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood, 108(10), 3295-301.

van Oers, M. H., Van Glabbeke, M., Giurgea, L., Klasa, R., Marcus, R. E., Wolf, M., Kimby, E., van t Veer, M., ... Hagenbeek, A. (2010). Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. Journal of clinical oncology, 28(17), 2853-8.

Vidal, L., Gafter-Gvili, A., Salles, G., Dreyling, M. H., Ghielmini, M., Hsu Schmitz, S. F., Pettengell, R., Witzens-Harig, M., & Shpilberg, O. (2011). Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials. Journal of the National Cancer Institute, 103(23), 1799-806.

Voong, K. R., McSpadden, K., Pinnix, C. C., Shihadeh, F., Reed, V., Salehpour, M. R., Arzu, I., Wang, H., ... Dabaja, B. S. (2014). Dosimetric advantages of a "butterfly" technique for intensity-modulated radiation therapy for young female patients with mediastinal Hodgkin's lymphoma. Radiotherapy and oncology, 9, 94.

Voss, M. H., Lunning, M. A., Maragulia, J. C., Papadopoulos, E. B., Goldberg, J., Zelenetz, A. D., & Horwitz, S. M. (2013). Intensive induction chemotherapy followed by early high-dose therapy and hematopoietic stem cell transplantation results in improved outcome for patients with hepatosplenic T-cell lymphoma: a single institution experience. Clinical lymphoma, myeloma & leukemia, 13(1), 8-14.

Vuolio, T., Kuittinen, O., Väyrynen, J. P., Teppo, H. R., Prusila, R. E. I., Rämet, M., Kuitunen, H., Paloneva, T., & Kuusisto, M. E. L. (2023). R-bendamustine in the treatment of nodular lymphocyte predominant Hodgkin lymphoma-An extended follow-up. British journal of haematology, 202(4), e24-e26.

Wang, H., Wan, X., Zhang, Y., Guo, J., & Bai, O. (2024). Advances in the treatment of relapsed/refractory marginal zone lymphoma. Frontiers in oncology, 14, 1327309.

Wang, M. L., Lee, H., Chuang, H., Wagner-Bartak, N., Hagemeister, F., Westin, J., Fayad, L., Samaniego, F., ... Zhang, L. (2016). Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. The Lancet. Oncology, 17(1), 48-56.

Wang, M. L., Rule, S., Martin, P., Goy, A., Auer, R., Kahl, B. S., Jurczak, W., Advani, R. H., ... Blum, K. A. (2013). Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. New England journal of medicine, 369(6), 507-16.

Wästerlid, T., Hartman, L., Szekely, E., & Jerkeman, M. (2017). Impact on survival of addition of etoposide to primary chemotherapy in diffuse large B-cell lymphoma: a Swedish Lymphoma Registry study. Hematological oncology, 35(2), 151-157.

Wästerlid, T., Hasselblom, S., Joelsson, J., Weibull, C. E., Rassidakis, G., Sander, B., & Smedby, K. E. (2021). Real-world data on treatment and outcomes of patients with primary mediastinal large B-cell lymphoma: a Swedish lymphoma register study. Blood cancer journal, 11(5), 100.

Weisenburger, D. D., & Armitage, J. O. (1996). Mantle cell lymphoma-- an entity comes of age. Blood, 87(11), 4483-94.

Wilkosz, P., Greggains, G. D., Tanbo, T. G., & Fedorcsak, P. (2014). Female reproductive decline is determined by remaining ovarian reserve and age. PLoS One, 9(10), e108343.

Willemze, R., Cerroni, L., Kempf, W., Berti, E., Facchetti, F., Swerdlow, S. H., & Jaffe, E. S. (2019). The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood, 133(16), 1703-1714.

Willemze, R., Jaffe, E. S., Burg, G., Cerroni, L., Berti, E., Swerdlow, S. H., Ralfkiaer, E., Chimenti, S., ... Meijer, C. J. (2005). WHO-EORTC classification for cutaneous lymphomas. Blood, 105(10), 3768-85.

Willemze, R., & Meijer, C. J. (2003). Primary cutaneous CD30-positive lymphoproliferative disorders. Hematology/oncology clinics of North America, 17(6), 1319-32, vii-viii.

Wilson, M. R., Eyre, T. A., Kirkwood, A. A., Wong Doo, N., Soussain, C., Choquet, S., Martinez-Calle, N., Preston, G., ... McKay, P. (2022). Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients. Blood, 139(16), 2499-2511.

Wilson, W. H., Grossbard, M. L., Pittaluga, S., Cole, D., Pearson, D., Drbohlav, N., Steinberg, S. M., Little, R. F., ... Balis, F. (2002). Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood, 99(8), 2685-93.

Wirth, A., Mikhaeel, N. G., Aleman, B. M. P., Pinnix, C. C., Constine, L. S., Ricardi, U., Illidge, T. M., Eich, H. T., ... Specht, L. (2020). Involved Site Radiation Therapy in Adult Lymphomas: An Overview of International Lymphoma Radiation Oncology Group Guidelines. International journal of radiation oncology, biology, physics, 107(5), 909-933.

Wittink, H., Michel, T. H. (2002). Chronic pain management for physical therapists. Elsevier Science.

Wong, J. Y. C., Filippi, A. R., Dabaja, B. S., Yahalom, J., & Specht, L. (2018). Total Body Irradiation: Guidelines from the International Lymphoma Radiation Oncology Group (ILROG). International journal of radiation oncology, biology, physics, 101(3), 521-529.

Wotherspoon, A. C., Doglioni, C., Diss, T. C., Pan, L., Moschini, A., de Boni, M., & Isaacson, P. G. (1993). Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet, 342(8871), 575-7.

Wundisch, T., Thiede, C., Morgner, A., Dempfle, A., Gunther, A., Liu, H., Ye, H., Du, M. Q., ... Neubauer, A. (2005). Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication. Journal of clinical oncology, 23(31), 8018-24.

Yahalom, J., Illidge, T., Specht, L., Hoppe, R. T., Li, Y., Tsang, R., & Wirth, A. (2015). Modern Radiation Therapy for Extranodal Lymphomas: Field and Dose Guidelines From the International Lymphoma Radiation Oncology Group. International journal of radiation oncology, biology, physics, 92(1), 11-31.

Younes, A., Gopal, A. K., Smith, S. E., Ansell, S. M., Rosenblatt, J. D., Savage, K. J., Ramchandren, R., Bartlett, N. L., ... Chen, R. (2012). Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. Journal of clinical oncology, 30(18), 2183-9.

Zaorsky, N. G., Williams, G. R., Barta, S. K., Esnaola, N. F., Kropf, P. L., Hayes, S. B., & Meyer, J. E. (2017). Splenic irradiation for splenomegaly: A systematic review. Cancer treatment and research, 53, 47-52.

Zhang, N., Xu, D., Liu, B., Shi, X., Xie, X., & Wang, Z. (2022). Prophylaxis strategies containing high dose intravenous methotrexate on preventing CNS relapse for patients with diffuse large B-cell lymphoma at intermediate to high risk: A study based on 12 cohorts in the rituximab era. International immunopharmacology, 113(Pt A), 109299.

Zhou, Z., Sehn, L. H., Rademaker, A. W., Gordon, L. I., Lacasce, A. S., Crosby-Thompson, A., Vanderplas, A., Zelenetz, A. D., ... Winter, J. N. (2014). An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood, 123(6), 837-42.

Zucca, E., Conconi, A., Laszlo, D., Lopez-Guillermo, A., Bouabdallah, R., Coiffier, B., Sebban, C., Jardin, F., ... Thieblemont, C. (2013). Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized Study. Journal of clinical oncology, 31(5), 565-72.

Zucca, E., Roggero, E., Bertoni, F., Conconi, A., & Cavalli, F. (1999). Primary extranodal non-Hodgkin's lymphomas. Part 2: Head and neck, central nervous system and other less common sites. Annals of oncology, 10(9), 1023-33.

Zucca, E., Rondeau, S., Vanazzi, A., Østenstad, B., Mey, U. J. M., Rauch, D., Wahlin, B. E., Hitz, F., ... the Nordic Lymphoma Group (2019). Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy. Blood, 134(4), 353-362.